Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H | ELISA, IF, WB | M | Purified | Monoclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | MAB13406 |
| Replaces | 04-1048 |
| Brand Family | Chemicon® |
| Trade Name |
|
| Description | Anti-MMP-2 Antibody, pro and active form, clone VB3 |
| Alternate Names |
|
| Product Information | |
|---|---|
| Format | Purified |
| Control |
|
| Presentation | 200 μg/mL. of antibody purified from ascites fluid by Protein G chromatography. Liquid in 10 mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | This Anti-MMP-2 Antibody, pro & active form, clone VB3 is validated for use in ELISA, IF, WB for the detection of MMP-2. |
| Key Applications |
|
| Applications Not Recommended |
|
| Application Notes | Western blot: 1:200-1:400 for 2 hours at room temperature ELISA Immunofluorescence Does not work for immunohistochemistry Optimal working dilutions must be determined by end user. |
| Biological Information | |
|---|---|
| Immunogen | Human native 72 kDa Gelatinase A. |
| Epitope | pro and active form |
| Clone | VB3 |
| Concentration | Please refer to the Certificate of Analysis for the lot-specific concentration. |
| Host | Mouse |
| Specificity | The antibody recognizes proteins of 72kDa and 66kDa which are identified as pro (latent) and active forms of matrix metalloproteinase-2 (MMP-2; also known as 72 kDa collagenase IV or gelatinase A). Shows no cross-reactivity with pro and active forms of other MMPs. MMPs are proteolytic enzymes capable of degrading connective tissue components. Degradation of the extracellular matrix (ECM) is an essential step in tumor invasion and metastasis. MMPs each have different substrate specificities within the ECM and are important in its degradation. MMP-2 mainly degrades type IV collagen and denatured collagens. MMP activity is modulated by tissue inhibitors of metalloproteinases (TIMP). Imbalanced secretion of certain MMP or disturbances in the differential control of MMP by TIMP have been implicated in the invasive potential of malignant tumors.Cellular Localization: cytoplasmic |
| Isotype | IgG1 |
| Species Reactivity |
|
| Antibody Type | Monoclonal Antibody |
| Entrez Gene Number |
|
| Entrez Gene Summary | Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMPs are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. This gene encodes an enzyme which degrades type IV collagen, the major structural component of basement membranes. The enzyme plays a role in endometrial menstrual breakdown, regulation of vascularization and the inflammatory response. Mutations in this gene have been associated with Winchester syndrome and Nodulosis-Arthropathy-Osteolysis (NAO) syndrome. |
| Gene Symbol |
|
| UniProt Number |
|
| UniProt Summary | FUNCTION: SwissProt: P08253 # In addition to gelatin and collagens, it cleaves KiSS1 at a Gly- -Leu bond. COFACTOR: Binds 4 calcium ions per subunit. & Binds 2 zinc ions per subunit. SIZE: 660 amino acids; 73882 Da SUBUNIT: Ligand for integrin alpha-V/beta-3. TISSUE SPECIFICITY: Produced by normal skin fibroblasts. DOMAIN: SwissProt: P08253 The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme. PTM: The propeptide is processed by MMP14 (MT-MMP1) and MMP16 (MT- MMP3). DISEASE: SwissProt: P08253 # Defects in MMP2 are the cause of multicentric osteolysis nodulosis and arthropathy (MONA) [MIM:605156]. Inherited osteolyses or vanishing bone syndromes are rare disorders of unknown etiology characterized by destruction and resorption of affected bones. MONA is an autosomal recessive osteolysis with multicentric involvement characterized by carpal and tarsal resorption, crippling arthritic changes, marked osteoporosis, palmar and plantar subcutaneous nodules and distinctive facies. & Defects in MMP2 are the cause of Winchester syndrome [MIM:277950]. Winchester syndrome is an autosomal recessive osteolysis syndrome. Winchester syndrome is severe with generalized osteolysis and osteopenia. Subcutaneous nodules are usually absent. Winchester syndrome has been associated with a number of additional features including coarse face, corneal opacities, patches of thickened, hyperpigmented skin, hypertrichosis and gum hypertrophy. However, these features are not always present and have occasionally been observed in other osteolysis syndromes. The clinical and molecular findings suggest that Winchester syndrome and MONA are allelic disorders that form a continuous clinical spectrum. SIMILARITY: Belongs to the peptidase M10A family. & Contains 3 fibronectin type-II domains. & Contains 4 hemopexin-like domains. |
| Product Usage Statements | |
|---|---|
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Maintain refrigerated at 2-8°C in undiluted aliquots for up to 12 months. |
| Packaging Information | |
|---|---|
| Material Size | 100 µg |